Corporate Corruption News Articles

Excerpts of key news articles on

Below are key excerpts of revealing news articles on corporate corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: Explore our full index to revealing excerpts of key major media news articles on dozens of engaging topics. And read excerpts from 20 of the most revealing news articles ever published.

EpiPen prices aren't the only thing to jump at Mylan. Executive salaries have also seen a stratospheric uptick. Proxy filings show that from 2007 to 2015, Mylan CEO Heather Bresch's total compensation went from $2,453,456 to $18,931,068, a 671 percent increase. During the same period, the company raised EpiPen prices, with the average wholesale price going from $56.64 to $317.82, a 461 percent increase. In 2007 the company bought the rights to EpiPen, a device used to provide emergency epinephrine to stop a potentially fatal allergic reaction and began raising its price. In 2008 and 2009, Mylan raised the price by 5 percent. At the end of 2009 it tried out a 19 percent hike. The years 2010-2013 saw a succession of 10 percent price hikes. And from the fourth quarter of 2013 to the second quarter of 2016, Mylan steadily raised EpiPen prices 15 percent every other quarter. After Mylan acquired EpiPen the company also amped up its lobbying efforts. In 2008, its reported spending on lobbying went from $270,000 to $1.2 million, according to opensecrets.org. Legislation that enhanced its bottom line followed, with the FDA changing its recommendations in 2010 that two EpiPens be sold in a package instead of one. And in 2013 the government passed a law to give block grants to states that required they be stocked in public schools.

Note: For more, see this CNBC article. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry.

Think tanks, which position themselves as “universities without students,” have power in government policy debates because they are seen as researchers independent of moneyed interests. But in the chase for funds, think tanks are pushing agendas important to corporate donors, at times blurring the line between researchers and lobbyists. And they are doing so while reaping the benefits of their tax-exempt status, sometimes without disclosing their connections to corporate interests. On issues as varied as military sales to foreign countries, international trade, highway management systems and real estate development, think tanks have frequently become vehicles for corporate influence and branding campaigns. “This is about giant corporations who figured out that by spending, hey, a few tens of millions of dollars, if they can influence outcomes here in Washington, they can make billions of dollars,” said Senator Elizabeth Warren, Democrat of Massachusetts, a frequent critic of undisclosed Wall Street donations to think tanks. Washington has seen a proliferation of think tanks, particularly small institutions with narrow interests tied to specific industries. At the same time, the brand names of the field have experienced explosive growth. [The Brookings Institution]’s annual budget has doubled in the last decade, to $100 million. The American Enterprise Institute is spending at least $80 million on a new headquarters in Washington, not far from where the Center for Strategic and International Studies built a $100 million office tower.

Note: Read more about how big money buys off institutions democracy depends on. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the corporate world.

For more than a decade, professional snoops have been able to search troves of ... addresses, DMV records, photographs of a person’s car - and condense them into comprehensive reports costing as little as $10. Now they can combine that information with the kinds of things marketers know about you, such as which politicians you donate to, what you spend on groceries, and whether it’s weird that you ate in last night, to create a portrait of your life and predict your behavior. IDI, a year-old company in the so-called data-fusion business, is the first to centralize and weaponize all that information for its customers. Chief Executive Officer Derek Dubner says the system isn’t waiting for requests from clients - it’s already built a profile on every American adult, including young people who wouldn’t be swept up in conventional databases, which only index transactions. These personal profiles include all known addresses, phone numbers, and e-mail addresses; every piece of property ever bought or sold, plus related mortgages; past and present vehicles owned; criminal citations, from speeding tickets on up; voter registration; hunting permits; and names and phone numbers of neighbors. The reports also include photos of cars taken by private companies using automated license plate readers - billions of snapshots tagged with GPS coordinates and time stamps to help PIs surveil people or bust alibis. IDI also runs two coupon websites ... that collect purchasing and behavioral data.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corporate corruption and the erosion of privacy.

A safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of dollars for pricey medications at taxpayer expense. The cost of Medicare’s “catastrophic” prescription coverage jumped by 85 percent in three years, from $27.7 billion in 2013 to $51.3 billion in 2015. Out of some 2,750 drugs covered by Medicare’s Part D benefit, two pills for hepatitis C infection - Harvoni and Sovaldi - accounted for nearly $7.5 billion in catastrophic drug costs in 2015. Medicare’s catastrophic coverage was originally designed to protect seniors with multiple chronic conditions from the cumulatively high costs of taking many different pills. Beneficiaries pay 5 percent after they have spent $4,850 of their own money. With some drugs now costing more than $1,000 per pill, that threshold can be crossed quickly. Lawmakers who created Part D in 2003 also hoped added protection would entice insurers to participate in the program. Medicare pays 80 percent of the cost of drugs above a catastrophic threshold that combines spending by the beneficiary and the insurer. That means taxpayers, not insurers, bear the exposure for the most expensive patients. Catastrophic spending accounts for a fast-growing share of Medicare’s drug costs, which totaled nearly $137 billion in 2015. The catastrophic share was 37 percent, yet only about 9 percent of beneficiaries reached the threshold for such costs. Catastrophic coverage will soon cost as much as the entire prescription program did when it launched. Experts say the rapid rise in spending for pricey drugs threatens to make the popular prescription benefit financially unsustainable.

Note: Read an excellent essay by former New England Journal of Medicine editor Dr. Marcia Angell exposing The Truth About the Drug Companies. For more along these lines, see concise summaries of deeply revealing Big Pharma profiteering news articles from reliable major media sources.

Genentech and another drugmaker will pay $67 million to settle claims that they misled doctors into prescribing a treatment to lung cancer patients for whom the companies knew it would not work. As a result, some patients may have died earlier than they would have if they had taken more effective drugs, a lawsuit brought by a former Genentech employee and joined by federal prosecutors alleges. From 2006 to 2011 Genentech and its marketing partner OSI Pharmaceuticals promoted Tarceva to treat all patients with non-small-cell lung cancer even though studies had shown that it worked for just those who had never smoked or had a certain gene mutation known as EGFR. Epidermal growth factor receptor is a type of protein found on the surface of cells in the body. The whistle-blower lawsuit was filed in 2011 by Brian Shields, who worked as a Tarceva sales representative and then a product manager. The lawsuit said the companies ... discouraged doctors from testing patients for EGFR. The companies also promoted Tarceva ... by giving doctors illegal kickbacks disguised as fees for making speeches or serving on Genentech’s advisory boards. Sales representatives across the country were “instructed to spend lavishly” on physicians, the case said, and given “an unlimited budget to wine and dine.” Genentech also organized lunches or dinners for lung cancer patients where “patient ambassadors” were paid fees to speak about how Tarceva could be used in ways never approved by regulators, the lawsuit said.

Note: While Genentech was inaccurately describing its new drugs to doctors and patients, this company was also fiercely lobbying to prevent others from selling affordable alternatives to its costly drugs. Practices like this, along with the suppression of promising cancer research, show how Big Pharma puts profit before people.

Prime ministers, finance ministers, leading entrepreneurs and a former spy chief are among the attendees at this year’s influential Bilderberg conference ... which begins on Thursday in Dresden. The German military has been drafted in to oversee security. They’re working with corporate security from Airbus to make sure the politicians are kept safely away from the press for the entire three-day conference. Every year, a major corporation with links to the Bilderberg steering committee coordinates security for the event with the police. Which makes the whole conference even more obviously the corporate lobbying event that it is - with giant corporations handling everything from security to dry ice. And it makes the silence of the politicians who attend even more egregious. These high-level talks between policymakers and the heads of transnational oil companies ... take place in heavily guarded privacy, with no press oversight whatsoever. [This is] especially great if you’re on the board of BP. Like, for example, Sir John Sawers. As well as being a director of BP, the silken, Blairish former MI6 boss is a member of Bilderberg’s steering committee, and the chairman of Macro Advisory Partners, a global advisory group with heavy links to the transatlantic intelligence community, very much in the style of Kissinger Associates. And speak of the devil! The ageless 93-year-old former US secretary of state will be holding court at Dresden, croaking out his wisdom from the throne of bones he has shipped everywhere he goes.

Note: This entire article is a must read if you want to know how the power elite work together to manipulate global politics. For more along these lines, see concise summaries of deeply revealing news articles on the Bilderberg Group and other elite secret societies.

More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. Clinical trials ... seemed to support their optimism. Patients needed just a fraction of the dose, creating the chance of far fewer dangerous side effects. But in 2004 ... Gilead executives stopped the research. The results of the early patient studies would go unpublished for years as the original medication - tenofovir - became one of the world’s most-prescribed drugs for HIV, with $11 billion in annual sales. In 2010, Gilead restarted those trials. A year of treatment with Gilead’s HIV medicines costs about $30,000. Earlier this year, the Los Angeles-based AIDS Healthcare Foundation, which operates clinics and pharmacies for AIDS patients, sued Gilead, contending that it delayed the less toxic form of tenofovir to manipulate the patent system and keep prices artificially high. Animal studies showed that [tenofovir] could cause damage to the kidneys and bones. When the drug was approved in 2001, the FDA required Gilead to study whether the medicine would harm humans in the same way. [By] 2003, the company had received so many reports of patients experiencing kidney failure and other ... problems that it placed a warning on the drug’s label. Several times, U.S. regulators formally warned Gilead that it was downplaying the drug’s risks.

Note: After the FDA warned Gilead that its sales reps were illegally lying to doctors about tenofovir's safety, Gilead continued misrepresenting this drug, prompting the FDC to send the company a rare second warning letter. For more along these lines, see concise summaries of deeply revealing big Pharma profiteering news articles from reliable major media sources.

You've heard those hospital horror stories where the surgeon removes the wrong body part or operates on the wrong patient. Even scarier, perhaps, is a new study in the latest edition of BMJ suggesting most medical errors go unobserved, at least in the official record. In fact, the study, from doctors at Johns Hopkins, suggests medical errors may kill more people than lower respiratory diseases like emphysema and bronchitis do. That would make these medical mistakes the third leading cause of death in the United States. That would place medical errors right behind heart disease and cancer. Through their analysis of four other studies examining death rate information, the doctors estimate there are at least 251,454 deaths due to medical errors annually in the United States. The authors believe the number is actually much higher, as home and nursing home deaths are not counted in that total. This is a much greater number than a highly cited 1999 study from the Institute of Medicine that put the number in the 44,000 to 98,000 range. Other studies have put estimates closer to 195,000 deaths a year. The U.S. Department of Health and Human Services Office of the inspector general in 2008 reported 180,000 deaths by medical error among Medicare patients alone. Dr. Martin Makary and Dr. Michael Daniel, who did the study, hope their analysis will lead to real reform in a health care system they argue is letting patients down.

Note: The above article does not mention prescription drug deaths. This is surprising, as prescription drugs were reported to have caused 123,000 deaths and 800,000 adverse patient outcomes such as disability in the US in 2014 alone. Read also the revealing comments of Marcia Angell, former editor-in-chief of the New England Journal of Medicine, on the massive corruption she found in the health industry. Then explore the excellent, reliable resources provided in our Health Information Center.

There aren’t many things upon which Hillary Clinton and Donald Trump agree. But the candidates for president share an affinity for the same ... office building in Wilmington. Famous for helping tens of thousands of companies avoid hundreds of millions of dollars in tax ... 1209 North Orange is home to Apple, American Airlines, Coca-Cola, Walmart and dozens of other companies. Being registered in Delaware lets companies take advantage of strict corporate secrecy rules, business-friendly courts and the “Delaware loophole”, which ... is said to have cost other states more than $9bn in lost taxes over the past decade. Both ... Hillary Clinton and Donald Trump have companies registered at 1209 North Orange, and have refused to explain why. Clinton, who has repeatedly promised that as president she will crack down on “outrageous tax havens and loopholes”, [has] collected more than $16m in public speaking fees and book royalties in 2014 through the doors of 1209. Bill Clinton set up WJC LLC, a vehicle to collect his consultation fees, at the same address in 2008. The Clintons’ companies share the office with several of Trump’s companies. They include Trump International Management Corp and several companies that form part of ... a Trump partnership to develop more than $1bn worth of luxury condos on the west side of Manhattan. Of the 515 companies on Trump’s official Federal Election Commission (FEC) filing, 378 are registered in Delaware.

Note: The above article adds to the evidence that the US, which ranks third in the world in financial secrecy, is a one-party state. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the financial industry.

A USA Today analysis of more than 1,000 American-based companies registered by Mossack Fonseca, the law firm at the heart of the Panama Papers leak, casts the United States openly into an uncomfortable role: an offshore haven of corporate secrecy for wealthy business operations across the globe. Both Nevada and Wyoming have become secretive havens much like Bermuda and Switzerland have long been. And at least 150 companies set up by Mossack Fonseca in those states have ties to major corruption scandals in Brazil and Argentina. The corporate records of 1,000-plus Nevada business entities linked to the Panamanian law firm reveal layers of secretive ownership, with few having humans' names behind them, and most tracing back to a tiny number of overseas addresses. For about 700 of the American shell companies, the corporate officers are business entities rather than people, meaning no individual is linked to the Nevada firm in state records. Matthew Gardner, executive director of the Institute on Taxation and Economic Policy, [said], “We should be thinking about this as a very American problem, and a problem that arguably is worse here in the states than it is in Panama.” In Wyoming, where Mossack Fonseca has also registered about two dozen companies, corporations are even harder to trace. Mossack Fonseca defended its practices and said incorporating companies in different jurisdictions is “the normal activity of lawyers and agents around the world.”

Note: A 2015 Guardian newspaper article further describes how the US helps the super-rich hide assets. For more along these lines, see concise summaries of deeply revealing financial industry corruption news articles from reliable major media sources.

The Rockefeller Family Fund, a charity that supports causes related to the environment, economic justice and other issues, is liquidating its investments in fossil fuel companies, including Exxon Mobil. "While the global community works to eliminate the use of fossil fuels, it makes little sense - financially or ethically - to continue holding investments in these companies," the fund said. In announcing its decision, the Rockefeller fund attacked Exxon for what it called the company's "morally reprehensible conduct," alluding to allegations that the company has hidden evidence that fossil fuels contribute to climate change. "Evidence appears to suggest that the company worked since the 1980s to confuse the public about climate change's march, while simultaneously spending millions to fortify its own infrastructure against climate change's destructive consequences and track new exploration opportunities as the Arctic's ice receded," the fund said. New York State Attorney General Eric Schneiderman is said to have launched an investigation last fall into whether Exxon misled the public and investors about ... climate risks. California Attorney General Kamala Harris is also reportedly looking into whether Exxon lied about climate change. The probes followed a report by InsideClimate News ... claiming that Exxon sought to undermine scientific evidence that pointed to the growing threat of climate change.

Note: The Rockefeller Brothers Fund announced its fossil fuel divestment in 2014. For more along these lines, see concise summaries of deeply revealing news articles on climate change and the corruption of science from reliable major media sources.

New research suggests that Splenda - an artificial sweetener recently considered safe - may contribute to serious health problems like cancer. The study, published in the International Journal of Occupational and Environmental Health, found that mice fed sucralose daily throughout their lives developed leukemia and other blood cancers. In response to the findings, the Center for Science in the Public Interest - a nutrition watchdog group that assesses the safety of food additives - has now formally recommended that consumers avoid the sweetener. That's a big deal, considering that until 2013, they'd rated the additive as "safe." This new evidence was especially powerful because it was funded without special interests in mind, explains Lisa Lefferts, MSPH, senior scientist at the CSPI. "For most food additives, the safety studies are conducted by the manufacturers who have financial incentives," Lefferts says. Even if you discount this new mouse study, you'll still find plenty of reasons to skip out on sucralose. A growing body of research shows that artificial sweeteners may actually cause weight gain, not weight loss. One study found drinking diet soda was linked to increased belly fat; in another, each daily can was associated with a 41% jump in obesity risk. Sucralose has even been shown to mess with your blood sugar and insulin levels, causing spikes and dips that could lead to cravings later on. The bottom line: the scientists at the CSPI firmly believe you should steer clear of sucralose.

Note: Food additive manufacturers use the same deceptive tactics that Big Tobacco was found guilty of. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.

Japan's prime minister at the time of the 2011 earthquake and tsunami has revealed that the country came within a “paper-thin margin” of a nuclear disaster requiring the evacuation of 50 million people. In an interview with The Telegraph ... Naoto Kan described the panic and disarray at the highest levels of the Japanese government as it fought to control multiple meltdowns at the crippled Fukushima Daiichi nuclear power station. He said he considered evacuating the capital, Tokyo, along with all other areas within 160 miles of the plant, and declaring martial law. Mr Kan admitted he was frightened and said he got “no clear information” out of Tepco, the plant’s operator. He was “very shocked” by the performance of Nobuaki Terasaka, his own government’s key nuclear safety adviser. “We asked him – do you know anything about nuclear issues? And he said no, I majored in economics.” Another member of Mr Kan’s crisis working group, the then Tepco chairman, Tsunehisa Katsumata, was last week indicted on charges of criminal negligence for his role in the disaster. Mr Kan lost the prime ministership later in 2011. The former leader said that “a lot of the accident was caused before March 11” by the complacency and misjudgment of Tepco, a verdict echoed by the official inquiry, which dubbed the nuclear accident a “man-made disaster”. The criminal investigation which led to last week’s charges against Mr Katsumata and two other Tepco managers found that they had known since June 2009 that the plant was vulnerable.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the Fukushima Nuclear Plant disaster.

Bill and Melinda Gates are facing calls for their philanthropic Foundation, through which they have donated billions worldwide, to be subject to an international investigation. The Gates Foundation is about benefiting big business, especially in agriculture and health, through its “ideological commitment to promote neoliberal economic policies and corporate globalisation,” according to [a] report published by the campaign group Global Justice Now. The report accuses the Gates Foundation of [turning] “basic needs into commodities controlled by the market.” The report is critical of the close working relations between the Foundation and major international pharmaceutical corporations. It accuses the Gates Foundation of promoting specific priorities through agriculture grants, some of which undermine the interests of small farmers. These include promoting industrial agriculture, use of chemical fertilisers and expensive, patented seeds, and a focus on genetically modified seeds. The criticism echoes the accusations made by the Indian scientist Vandana Shiva who called the Gates Foundation the “greatest threat to farmers in the developing world.” The Foundation’s emphasis on “technological solutions” often ignores real solutions involving social and economic justice. “This cannot be given by donors in the form of a climate-resilient crop or cheaper smartphone, but must be about systemic social, economic and political change – issues not represented in the foundation’s funding priorities.”

Note: The Gates Foundation is heavily invested in GMO giants like Monsanto. It also provided $5 million to Oxitec, a company criticized for secretly releasing GM mosquitoes into the wild in 2009. Oxitec was purchased last August by biotech giant Intrexon for $160 million. By December, the Zika virus was all over the news and Intrexon was ramping up production of these GM insects to "fight Zika" in Brazil. For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.

After Martin Shkreli raised the price of anti-parasitic drug Daraprim more than 50-fold to $750 a pill last year, he said he wasn’t alone in taking big price hikes. The former drug executive was right. A survey of about 3,000 brand-name prescription drugs found that prices more than doubled for 60 and at least quadrupled for 20 since December 2014. Skyrocketing prices are getting increased scrutiny ahead of a U.S. congressional hearing this week: Democratic Representative Elijah Cummings, ranking member on a committee that is probing drug pricing, said Tuesday that pricing “tactics are not limited to a few ‘bad apples,’ but are prominent throughout the industry.” The cost of many drugs [rises] at annual rates of more than 10 percent. Drugmakers raised the prices of products as wide-ranging as erectile dysfunction drug Viagra, heart treatments, dermatology medicine and even brands that long have lost their patents. While specialty companies have had the steepest hikes, giants such as Pfizer Inc. and GlaxoSmithKline Plc kept pushing through smaller rises. About 400 formulations of brand-name drugs went up at least 9.9 percent since early December. Valeant Pharmaceuticals International Inc., which in recent months has been under fire for its pricing was among the most aggressive, with 13 drugs that doubled or more since December 2014.

Note: For more excellent information on drug prices hikes, read this penetrating article in the Daily Beast. For more along these lines, see concise summaries of deeply revealing big pharma profiteering news articles from reliable major media sources.

Massachusetts Senator Elizabeth Warren issued a stinging broadside against federal prosecutors on Friday, charging U.S. courts with throwing the book at mixed-up teenagers, while letting wealthy corporate executives who commit much larger and sometimes deadly crimes off with essentially no chance of punishment. In a new report, Sen. Warren’s office makes the case that CEOs and other top executives simply don’t face the same legal consequences as ordinary Americans, releasing a list of what it claims are 20 examples of corporate criminal and civil cases that prosecutors failed to pursue to the full extent of the law last year. Among the cases: scandals ranging from General Motors’ years’ long cover up of ignition switch problems to currency manipulation by large banks (including Citigroup and J.P. Morgan), to a mine explosion that killed 29 people - the only instance of misconduct which led to a conviction of a corporate executive. Such selective application of the law undermines the government’s moral authority: “If justice means a prison sentence for a teenager who steals a car, but it means nothing more than a sideways glance at a CEO who quietly engineers the theft of billions of dollars, then the promise of equal justice under the law has turned into a lie,” Warren charges in the report. It’s not just a problem in the U.S. This week, U.K. prosecutors, after winning an initial conviction in their quest to prosecute bankers accused of fixing LIBOR - a key benchmark central to financial markets - failed to secure any further wins.

Note: Senator Elizabeth Warren was called "the champion of Main Street versus Wall Street" by the Boston Globe in 2014. For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and in the corporate world.

Soon after launching a brutal air and ground assault in Yemen, the Kingdom of Saudi Arabia began devoting significant resources to a sophisticated public relations blitz. Elements of the charm offensive include the launch of a pro-Saudi Arabia media portal operated by high-profile Republican campaign consultants; a special English-language website devoted to putting a positive spin on the latest developments in the Yemen war; glitzy dinners with American political and business elites; and a non-stop push to sway reporters and policymakers. That has been accompanied by a spending spree on American lobbyists with ties to the Washington establishment. Saudi Arabia continues to be a leading driver of Sunni terror networks worldwide, including in Syria and Iraq. The Saudi Arabian government is currently supplying weapons to a Syrian rebel coalition that includes the Nusra Front, al Qaeda’s affiliate in the region. Private donors in Saudi Arabia have also worked as fundraisers for the Islamic State, or ISIS. And there is a renewed, bipartisan push by lawmakers to declassify the 28 pages of the 9/11 Commission Report, a censored section that reportedly relates to Saudi state support for al Qaeda’s operation. In September, the Kingdom helped sponsor opulent galas for Washington’s business elite at the Ritz Carlton and the Andrew Mellon Auditorium. The events were attended by King Salman, along with the chief executives of General Electric and Lockheed Martin, the chairman of Marriott International, and prominent think tank officials.

Note: A carefully researched report on the covert origins of ISIS suggests the creation of terrorists is useful for Washington's elite. A document that is reported to connect Saudi money to 9/11 remains classified. For more along these lines, see concise summaries of deeply revealing news articles about government corruption and media manipulation.

According to the New York Department of Financial Services, a banking regulator, Goldman hired Rohit Bansal from the Federal Reserve Bank of New York in May 2014, "in large part for the regulatory experience and knowledge he had gained while working at the New York Fed." Goldman hired Bansal despite the fact that he had been forced to resign from the Fed for breaking the rules there. Once at Goldman, Bansal was instructed to work on a bank that he had supervised while at the Fed, despite explicit prohibitions against him doing so, NYDFS said. Bansal later used confidential information, some of which he obtained from his prior employment at the NY Fed and some of which he obtained from from a former NY Fed colleague, in his work on the bank. To resolve the matter, Goldman has agreed to pay $50 million and accept a three-year "voluntary abstention" from accepting new consulting engagements of NYDFS regulated entities. Goldman also agreed to admit that a former employee engaged in the criminal theft of confidential information and that Goldman management "failed to effectively supervise its employee to prevent this theft from occurring," NYDFS said. In September 2014, for example, Bansal attended the birthday dinner of a former Fed colleague at Peter Luger's. Immediately after the dinner, Bansal emailed his boss at Goldman "divulging confidential information concerning the regulated entity, specifically, the relevant component of the upcoming examination rating," NYDFS said.

Note: For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and in the financial industry.

A former Goldman Sachs banker suspected of taking confidential documents from a source inside the government has agreed to plead guilty, a rare criminal action on Wall Street, where Goldman itself is facing an array of regulatory penalties over the leak. The banker and his source, who at the time of the leak was an employee at the Federal Reserve Bank of New York, one of Goldman’s regulators, will accept a plea deal from federal prosecutors that could send them to prison for up to a year. Under a tentative deal ... Goldman would pay a fine of $50 million. For Goldman and the New York Fed, the case is likely to give new life to an embarrassing episode that illustrated the blurred lines between their institutions. Perhaps more than any other bank, Goldman swaps employees with the government, earning it the nickname “Government Sachs.” While the so-called revolving door is common on Wall Street, the investigation [affirms] the public’s concerns that regulators and bankers, when intermingled, occasionally form unholy alliances. The Goldman banker, Rohit Bansal, previously spent seven years as a regulator at the New York Fed.

Note: For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and in the financial industry.

Law firms around the United States are lining up plaintiffs for what they say could be "mass tort" actions against agrichemical giant Monsanto Co that claim the company's Roundup herbicide has caused cancer in farm workers and others exposed to the chemical. The latest lawsuit was filed Wednesday in Delaware. The lawsuit is similar to others filed last month in New York and California accusing Monsanto of long knowing that the main ingredient in Roundup, glyphosate, was hazardous. Monsanto "led a prolonged campaign of misinformation to convince government agencies, farmers and the general population that Roundup was safe," the lawsuit states. The litigation follows the World Health Organization's declaration in March that there was sufficient evidence to classify glyphosate as "probably carcinogenic to humans." "We can prove that Monsanto knew about the dangers of glyphosate," said Michael McDivitt, whose Colorado-based law firm is putting together cases for 50 individuals. Roundup ... brought Monsanto $4.8 billion in revenue in its fiscal 2015. But questions about Roundup's safety have dogged the company for years. Attorneys who have filed or are eying litigation cited strong evidence that links glyphosate to non-Hodgkin lymphoma. Monsanto is also fending off claims over its past manufacturing of polychlorinated biphenyls (PCBs), which the WHO classifies as known carcinogens. At least 700 lawsuits against Monsanto or Monsanto-related entities are pending.

Note: It's interesting to note that a Google search shows almost no major media picked up this key news. Read how the EPA used industry studies while ignoring independent studies to declare Roundup safe. Read also an excellent mercola.com article titled "GMO cookie is crumbling." Monsanto is trying to stop the state of California from listing Glyphosate as carcinogenic. For more along these lines, see concise summaries of deeply revealing GMO news articles from reliable major media sources.

Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.